The Peptide Field. Melanotan II: approval and evidence record.

Editorial review: 2026-07-31. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/melanotan-ii

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=melanotan-ii#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No approved product in any jurisdiction reviewed

Exact product limits: A label on a vial or nasal spray does not show that its contents match the name. The reviewed records identify no approved melanotan II product or product label. Laboratory analysis of products sold as melanotan II found less material than the label claimed and found unidentified impurities.

Human outcomes: Limited. No trial has tested whether using melanotan II makes anyone better off on any patient-centred endpoint.

Body effects in people: Limited. Two small human studies from 1996 and 2000 measured pigmentation and erectile response; no human pharmacokinetic or intranasal data was located.

What the evidence shows: Two small studies in people found changes in pigment and sexual response, but they do not establish safe or effective use. The published harm record includes case reports of severe muscle breakdown, kidney injury, a prolonged painful erection that needed emergency treatment, and melanoma reported after melanotan use. These reports show that serious events were reported. They cannot show how often an event occurs or prove that Melanotan II caused each event.

What remains unknown: The evidence does not show how often serious harms occur or what one person's risk is. The review found no phase 2 or phase 3 trial, no long-term safety study, no human study of nasal-spray absorption, and no comparison with afamelanotide. The case reports do not establish whether Melanotan II causes melanoma. Some reports also involved sunbeds or other ultraviolet exposure. No cohort or registry study was found. The frequency of serious harm is unknown; it is not known to be low.

Safety limits: Ischaemic priapism is a time-critical emergency: an erection persisting beyond about four hours needs immediate emergency care, because delay carries a risk of permanent erectile dysfunction. Anyone with a changing, darkening or new mole should be assessed by a clinician. This guide gives no dose, route, source or administration guidance, and none of the case-report harms below can be translated into a personal risk estimate.

Approval claim: “Melanotan II is legal because it is sold as a research chemical.”
Verdict: Misleading. Research-use-only wording is a marketing label, not a legal status for human use. Selling and supplying melanotan injections is illegal in the UK. Australia's regulator treats melanotan II as a prescription-only medicine that is unapproved, and issued one supplier 27 infringement notices totalling AU$101,412. That same research-chemical channel is the one whose products were found to contain roughly 43 to 88 per cent of the labelled amount plus unidentified impurities.
Evidence basis: Regulatory or product record. Scope: The legality of sale and supply, which is where enforcement in these jurisdictions is directed; it says nothing about what happens to an individual purchaser.
Claim sources: https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/sun-uv-and-cancer/fake-tan-and-melanotan-injections https://www.tga.gov.au/news/media-releases/individual-issued-27-infringement-notices-allegedly-supplying-melanotan-ii https://pubmed.ncbi.nlm.nih.gov/24771717/

Sources used in the full review (a source is not support for every claim):

PubMed · Life Sciences. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide, in a pilot phase-I clinical study. 1996. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/8637402/

PubMed · International Journal of Impotence Research. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. 2000. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/11035391/

PubMed · Clinical Toxicology. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. 2012. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/23121206/

PubMed Central · CEN Case Reports. Melanotan II: a possible cause of renal infarction — review of the literature and case report. 2020. Accessed 2026-07-31. https://pmc.ncbi.nlm.nih.gov/articles/PMC7148395/

PubMed · Sexual Medicine. Melanotan tanning injection: a rare cause of priapism. 2021. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/33460908/

PubMed · Dermatology. Melanoma associated with the use of melanotan-II. 2014. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/24355990/

PubMed · International Journal of Oral and Maxillofacial Surgery. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. 2025. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/40210573/

PubMed · International Journal of Dermatology. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. 2017. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/28266027/

PubMed · Drug Testing and Analysis. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the internet. 2015. Accessed 2026-07-31. https://pubmed.ncbi.nlm.nih.gov/24771717/

DailyMed · U.S. National Library of Medicine. SCENESSE (afamelanotide) prescribing information. 2026. Accessed 2026-07-31. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48

DailyMed · U.S. National Library of Medicine. VYLEESI (bremelanotide) prescribing information. 2026. Accessed 2026-07-31. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

European Medicines Agency. Scenesse European public assessment report. 2014. Accessed 2026-07-31. https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse

Cancer Research UK. Fake tan and melanotan injections. 2026. Accessed 2026-07-31. https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/sun-uv-and-cancer/fake-tan-and-melanotan-injections

Therapeutic Goods Administration. Individual issued 27 infringement notices for allegedly supplying melanotan II. 2024. Accessed 2026-07-31. https://www.tga.gov.au/news/media-releases/individual-issued-27-infringement-notices-allegedly-supplying-melanotan-ii

World Anti-Doping Agency. WADA Prohibited List. 2026. Accessed 2026-07-31. https://www.wada-ama.org/en/prohibited-list

U.S. Anti-Doping Agency. 2026 WADA Prohibited List summary. 2026. Accessed 2026-07-31. https://www.usada.org/spirit-of-sport/2026-wada-prohibited-list/

Keep the limits, review date, and sources with this record. Check the current source for changes.